4.5 Review

Challenges with matrix metalloproteinase inhibition and future drug discovery avenues

期刊

EXPERT OPINION ON DRUG DISCOVERY
卷 16, 期 1, 页码 75-88

出版社

TAYLOR & FRANCIS LTD
DOI: 10.1080/17460441.2020.1819235

关键词

Antibodies; drug design; drug discovery; hemopexin-like domain; matrix metalloproteinase; medicinal chemistry; polypharmacology; small-molecule inhibitors

资金

  1. Zurich University of Applied Sciences [AS-2020-1]

向作者/读者索取更多资源

Matrix metalloproteinases have been a promising target for drug development for decades, with no successful modulators surviving clinical trials so far. Despite this, ongoing research in MMP modulation shows that the target class remains attractive to pharmaceutical research, with potential for successful clinical therapies in the future.
Introduction Matrix metalloproteinases have been in the scope of pharmaceutical drug discovery for decades as promising targets for drug development. Until present, no modulator of the enzyme class survived clinical trials, all failing for various reasons. Nevertheless, the target family did not lose its attractiveness and there is ever more evidence that MMP modulators are likely to overcome the hurdles and result in successful clinical therapies. Areas Covered This review provides an overview of past efforts that were taken in the development of MMP inhibitors and insight into promising strategies that might enable drug discovery in the field in the future. Small molecule inhibitors as well as biomolecules are reviewed. Expert opinion Despite the lack of successful clinical trials in the past, there is ongoing research in the field of MMP modulation, proving the target class has not lost its appeal to pharmaceutical research. With ever-growing insights from different scientific fields that shed light on previously unknown correlations, it is now time to use synergies deriving from biological knowledge, chemical structure generation, and clinical application to reach the ultimate goal of bringing MMP derived drugs on a broad front for the benefit of patients into therapeutic use.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据